Estrogens are known to induce the expression of the receptor for advanced glycation end products (RAGE). In the current investigation, we examined the effect of three estrogens with different potency for specific estrogen receptors (ER) on RAGE expression in human microvascular endothelial cells (HMEC-1). Of the three estrogens tested, ethinyl estradiol (EE), an estrogen receptor alpha (ERa) agonist, was the strongest inducer of RAGE expression in HMEC-1. By comparison, 17-epiestriol, an estrogen receptor beta (ERh) agonist and 17-h-E 2 , an ER agonist that is almost equally potent for ERa and ERh were less effective in stimulating RAGE expression. We then determined whether the prooxidative and proinflammatory transcription factors Sp1 or NF-nB were downstream modulators of ER-agonists that mediate RAGE expression. The results implicated Sp1 but not NF-nB in estrogen-dependent RAGE expression. We further demonstrated that ERa but not ERh was responsible for the estrogen-mediated Sp1 activation. In summary, the present investigation demonstrates that a direct interaction of EE-ERa-Sp1 plays a central role in estrogen-induced RAGE expression in HMEC-1. D
Introduction
In diabetes, the receptor for advanced glycation end products (RAGE), a member of immunoglobulin super family of cell surface proteins [1] , acts as a progression factor by amplifying inflammatory and immune responses and likely contributes to the pathobiochemistry of cardiovascular diseases [2] [3] [4] [5] . Recent studies indicate that 17-h-E 2 , an estrogen, stimulates RAGE expression in endothelial cells [6] . The estrogen-dependent stimulation of RAGE expression is an estrogen receptor (ER)-dependent transcriptional process [6] . Of note, however, the action of estrogens can be vastly different depending on which of the two ER isotypes is involved, the ''classical'' ERa or the more recently demonstrated ERh [7] . Thus, to better understand the basis for the estrogen-dependent RAGE expression it is important to determine the specific role of ERa and ERh.
To date, no ERa or ERh specific antagonists have been developed. Therefore, investigators have relied on specific agonists to examine ER-dependent modulation of different genes. The affinity of various estrogenic compounds for the two ER subtypes markedly differs. 17-h-E 2 is a circulating estrogen predominantly found in the blood of premenopausal women. 17-h-E 2 binds to ERa and ERh with approximately equal affinity [8] . In contrast, 17-a-ethinylestradiol (EE) is a synthetic estrogen widely used in oral contraceptive formulations. EE has ERa selective agonistic potency [8] . 17-epiestriol, an estrogen metabolite generated in vivo [9] , has ERh selective agonistic potency [8] . Since EE and 17-epiestriol are ERa and ERh-agonists, respectively, treatment of endothelial cells with these compounds may provide insight into receptor type specific activation/ modulation of RAGE expression by estrogens. In target genes that lack estrogen response elements (EREs), estrogens interact at nonclassical response sites through protein -protein interactions between ER and transcription factors such as NF-nB, AP1, Sp1 or GATA [10 -13] . While no EREs have been identified upstream of the RAGE gene [6] , the promoter contains consensus sequences that are specific for binding the transcription factors Sp1 and NF-nB [14] . Activation of Sp1 is important in 17-h-E 2 -dependent activation of RAGE expression; however, the specific roles of ERa and ERh agonists have not been determined [6] . Similarly, although NF-nB is one of the important activators of various proinflammatory and prooxidative genes that can induce RAGE expression [6, 14] , the role of NF-nB in ERa-and ERh-dependent modulation of RAGE expression is not known.
The present investigation was designed to determine the mechanism that induces RAGE expression following interaction between ER-agonists with different ER. The studies were undertaken in human microvascular endothelial cells that have high-levels of RAGE expression and are involved in diabetic vasculopathy [15] . The studies addressed (1) the role of ERa and ERh-specific agonists in the estrogendependent induction of RAGE expression. (2) The effect of antisense/sense oligodeoxynucleotides of ERa and on the estrogen-dependent expression of RAGE. (3) The role of ERa and ERh specific agonists in the estrogen-dependent modulation of the transcription factors Sp1 and NF-nB, and their subsequent effect on RAGE expression.
Materials and methods

Chemicals
Medium M199, HEPES buffer, l-glutamine and collagenase-type 1 were obtained from Invitrogen Corporation. Charcoal/dextran-treated FBS and untreated FBS were obtained from Hyclone Laboratories. Gelatin, endothelialderived growth factor, 17-h-E 2 , EE, 17-epiestriol were obtained from Sigma Chemical Co. ICI182780 was obtained from Tocris Cookson Limited. Monoclonal anti-RAGE, anti-GAPDH and HRP-conjugated secondary antibodies were obtained from Chemicon International.
Culture and treatment of human microvascular endothelial cells (HMEC-1)
HMEC-1 (a kind gift from JF Candal, Center for Disease Control, Atlanta, GA) were cultured as described previously [16] in 20% FBS containing M199 medium. Before treatment, 90 -100% confluent cells were washed with M199 medium, and incubated overnight (O/N) with phenol red, glucose and serum-free M199 supplemented with 2 mM lglutamine and antibiotics. The following morning, the media was discarded and HMEC-1 was treated with the ER agonists in fresh media for 2 -4 h.
Reverse transcription-PCR for ERa and ERb mRNA
RNA extraction and purification were done using an RNeasy mini kit as described in the manufacturer's protocol (Qiagen). Total RNA (3 Ag per sample) was subjected to reverse transcription (RT) reactions using 50 units of Moloney murine leukemia virus reverse transcriptase at 42 -C for 25 min [10] . The resulting cDNA samples were PCR-amplified using a Gene Amp RNA PCR kit (Perkin Elmer Life Sciences). Oligonucleotide primers were designed for simultaneous PCR amplification of specific DNA fragments contained in both ERa and ERh using the following primer set: forward primer sequence, 5V-AAGAGCTGCCAGGCCTGCCG-3V; reverse primer sequence, 5V-GCCCAGCTGATCATGTGAACCA-3V [17] . The primer pair simultaneously generated a 382-bp fragment for ERa and a 346-bp fragment for ERh. These primers were tested on ERa and ERh cDNA plasmid clones to ensure that they generated the specific products targeted, with equivalent efficiency under the same amplification conditions [17] . For the detection of RAGE, the following primer sequences were used: F-5V-ATGGAAACTGAACACAGGCC-3V and R-5V-CACA-CATGTCCCCACCTTAT-3V [18] .
Western blotting
Western blotting was performed as described previously [10] . Following each treatment, the cells were lysed in a buffer containing 50 mM HEPES (pH 7.5), 1 mM DTT, 150 mM NaCl, 1 mM EDTA, 0.5% Tween-20, 10% glycerol, 10 mM h-glycerophosphate, 1 mM NaF, 0.1 mM orthovanadate, 10 Ag/ml leupeptin, 10 Ag/ml aprotinin and 0.1 mM phenylmethylsulfonyl fluoride. Then, 40 Ag of total protein was subjected to SDS-PAGE and transferred to a polyvinylidene difluoride membrane using a semi-dry transfer apparatus. Membranes were treated with monoclonal anti-RAGE Ab (1:1500, Chemicon International) O/N at 4 -C. HRPconjugated secondary antibody (Chemicon International) was used at the dilution of 1:20,000. Signals were developed using the ECL detection system (Amersham Bioscience). GAPDH was used as an internal control.
Electrophoretic mobility shift assay
EMSA was performed as described previously with modifications [10] . After each treatment, 1 Â 10 8 cells were washed twice with ice-cold phosphate-buffered saline (PBS), and nuclear extracts were prepared using a nuclear extract kit from Active Motif. The cell debris was pelleted by centrifugation, and nuclear proteins in the supernatant were quantitated by Bradford reagent (BioRad). The gel shift and supershift assays were performed using a Nushift Kit (Active Motif) with 10 Ag of nuclear extract from each treatment condition and 60 pmol of radiolabeled oligodeoxynucleotides for Sp1 or NF-nB. The specific sequence used for Sp1 was: ATTCGATCGGGGCGGGGCGAGC (5V-3V) and for NF-nB was: AGTTGAGGGGACTTTCC-CAGGC (5V-3V). For Supershift assays, 4 Al of rabbit polyclonal anti-NF-nB-p65 antibody (Active Motif), ERa (Santa Cruz Biotechnology) or ERh (Active Motif) antibodies were used.
Transient transfection of HMEC-1 with antisense and sense oligodeoxynucleotides
Phosphorothioate-modified oligodeoxynucleotides (ODN) were designed and synthesized at University of Utah Molecular Biology Core Facility as previously reported [19] . For transfection studies, 1.5 Â 10 5 HMEC-1 were seeded into 0.1% gelatin coated 35 mm plates and grown in the presence of complete M199 medium. Cells having confluency of 40-60% were washed just before transfection with EGM-MV medium (Clonetics) containing 2% FBS but no antibiotics. For transfection, antisense ODN of required concentrations (300 nM to 3 AM) were mixed with 92 Al (final volume) of EGM-MV medium without any serum, growth factors or antibiotics, mixed and added into 8 Al of SuperFect reagent (Qiagen). The mixture (total volume 100 Al) was incubated at room temperature for 15 min to allow complex formation. Following complex formation, 600 Al of EGM-MV medium containing 2% FBS but without antibiotics/other additives were added to the DNA-SuperFect complex (100 Al), mixed and the total volume (700 Al) was added drop-wise onto the cell culture plate. The plates were further incubated for 6-8 h at 37 -C to allow for uptake of DNA. Following transfection, cells were washed with complete M199 medium and incubated for an additional 24 h. This resulted in 90-100% confluent cells that were then treated with estrogens as mentioned in the protocol. For determination of transfection efficiency, cells were transfected with pGL3 vector regulated by the SV40 promoter and encoding for firefly luciferase (Promega). HMEC-1 have a transfection efficiency of 70-75% and antisense ODN can inhibit up to 90% of the related protein expression. Of note, more than 95% transfection efficiency was reported using Cytofectin GCV or SuperFect reagent on cultured human iliac artery endothelial cells [20] . Following treatment, cells were harvested for Western blot analysis. Normalization of the data was done using GAPDH as an internal control.
Plasmid construction, mutagenesis, transfection and reporter assays
Primers were designed to obtain the promoter sequence of the RAGE gene [6] . The resulting product was ligated into a luciferase-reporting vector (pGL-3-RAGE). Using the GeneEditori site-directed mutagenesis system (Promega), mutant Sp1 binding sites at À189, À172, or the simultaneous mutation of the sites at À189 and À172 were introduced into the RAGE promoter. The fidelity of each wild type or mutant promoter construct was verified by sequencing.
For transfection, HMEC-1 were plated onto gelatin-fixed 6-well dishes and allowed to adhere to the substrate for 4-5 h. Cells were then transfected with 100 ng pGL-3-RAGE and 500 ng RSV-hgal using FuGENE-6 transfection reagent (Roche). Media was changed 18 h after transfection and 0, 3, 10 or 30 nM EE was then added. Cells were lysed 4 h later and luciferase activities normalized to h-gal expression were measured using the Luciferase Reporter Assay System (Promega) and a MicroLumat LB 96P luminometer.
Statistical analysis
Values are expressed as mean T S.D. obtained from at least three separate experiments in each group. Differences between the groups were assessed by one-way analysis of variance and Newman-Keuls multiple comparison test. Results having P values <0.05 were considered significant. Each figure is representative three or four experiments.
Results
Effect of 17-b-E 2 on mRNA and protein expression of RAGE in HMEC-1
HMEC-1 were treated with various concentrations of 17-h-E 2 (100 pM to 10 nM) for 2 h or 4 h for the deter- mination of RAGE mRNA or protein expression, respectively. The results demonstrate that treatment of HMEC-1 with 100 pM to 10 nM concentrations of 17-h-E 2 caused a dose-dependent induction of expression of RAGE mRNA ( Fig. 1) and protein ( Fig. 2) with maximum induction at 10 nM.
Effect of ICI182780 on the 17-b-E 2 -dependent expression of RAGE in HMEC-1
To determine whether estrogen receptors are involved in estrogen-dependent RAGE expression in HMEC-1, we first determined the expression of specific estrogen receptors in HMEC-1 by RT-PCR. HMEC-1 expressed both ERa and ERh mRNA (data not shown). Next, we examined whether estrogen receptors were involved in 17-h-E 2 -dependent induction of RAGE. Towards this end, we treated HMEC-1 with ICI182780 prior to treatment with 10 nM 17-h-E 2 for 4 h. ICI182780 is a competitive inhibitor of estrogens that binds to both ERa and ERh. ICI182780 dose-dependently attenuated 17-h-E 2 -mediated stimulation of RAGE protein expression in HMEC-1 (Fig. 3) , indicating that estrogen receptors are involved in the 17-h-E 2 -dependent RAGE expression.
Effect of EE and 17-epiestriol on the expression of RAGE in HMEC-1
To determine which specific ER was responsible for the estrogen-mediated induction of RAGE expression, we treated HMEC-1 with the selective ERa agonist EE, or the selective ERh agonist 17-epiestriol for 4 h at the concentrations indicated in Fig. 4 . When compared with 17-h-E 2 , EE induced RAGE expression in a similar pattern but with higher potency. The maximum increase in RAGE protein expression by EE was 87T8% at 1 nM concentration ( Fig. 4A) . In contrast, 17-epiestriol only modestly stimulated RAGE protein expression and at 10 nM showed a maximum stimulation of 45 T 5% (Fig. 4B) . The comparative ability of 17-h-E 2 , EE and 17-epiestriol to induce RAGE protein expression is graphically represented in Fig.  5 . EE, the most potent estrogen studied, had its maximum effect at 1 nM. These concentrations of estrogens (100 pM to 1 nM) are found in the circulation of nonpregnant women indicating the possible involvement of estrogen in the induction of RAGE expression in nonpregnant women.
Effect of antisense ODN of ERa and ERb on the 17-b-E 2 -dependent RAGE expression in HMEC-1
To further investigate the relationship between 17-h-E 2 -dependent expression of RAGE and the role of different ER, HMEC-1 were pre-incubated with antisense ODN of ERa and ERh. 17-h-E 2 -dependent RAGE expression was inhibited dose dependently by incubating HMEC-1 for 6 h with antisense ODN of ERa prior to the treatment with 17- 5) . However, the sense ODN of ERa (3 AM) showed no significant effect on 17-h-E 2 -dependent RAGE expression (lane 6). *Indicates significant inhibition of RAGE protein expression by antisense ODN of ERa ( P < 0.05) as compared to the only 17-h-E 2 -treated cells (lane 2).
h-E 2 . The sense ODN of ERa had no significant effect on 17-h-E 2 -dependent RAGE expression (Fig. 6) . In contrast, neither the sense nor the antisense ODN of ERh effected 17-h-E 2 -dependent RAGE expression (Fig. 7) . These results indicate that 17-h-E 2 -dependent RAGE expression is mediated by ERa.
Effect of 17-b-E 2 , EE and 17-epiestriol on the activation of Sp1 in HMEC-1
Gel shift and supershift assays were used to identify the transcription factors involved in estrogen-dependent RAGE induction, focusing initially on the role of Sp1. Nuclear extracts were prepared from 17-h-E 2 , EE or 17-epiestriol treated HMEC-1 and used in gel shift assays (Fig. 8) . The intensity of the Sp1 band in the untreated nuclear extract (lane 3) is compared with nuclear extracts obtained from HMEC-1 treated with 17-h-E 2 , EE or 17-epiestriol in lane 4 to lane 8. EE treated HMEC-1 showed maximum intensity of the Sp1 band (lane 7), followed by 17-h-E 2 (lane 4). The lowest intensity was observed in 17-epiestriol-treated HMEC-1 (lane 8). The specificity of the Sp1 band was determined with a mutant Sp1 oligodeoxynucleotide where no band was observed (lane 2). To determine specific estrogen receptor-dependent activation of Sp1, we incubated 17-h-E 2 -treated nuclear extracts with ERa (lane 5) or ERh (lane 6) antibodies, respectively. The 17-h-E 2 -treated nuclear extracts were used for these supershift assays because the agonist interacts with both ERa and ERh almost equally. A supershift of the Sp1 band (lane 5) was observed with the ERa antibody that was similar to the supershift following treatment with the Sp1 antibody itself (data not shown). ERh antibody failed to produce a shift (lane 6). The intensity of the Sp1 band induced by the ERa agonist EE (lane 5) and a shift of the Sp1 band by treatment of 17-h-E 2 -treated nuclear extracts with ERa antibody further implicate involvement ERa in the process.
Role of Sp1 in EE activation of the RAGE /Promoter
We further analyzed the role of Sp1 elements in EEinduced RAGE promoter activity using luciferase promoter reporter constructs. Analysis of the 751-bp RAGE promoter reveals that 3 Sp1 sites (À189, À172, À45) are located upstream of the start site (Fig. 9A) . To determine the importance of these sites in promoter activity, HMEC-1 cells were transfected with a luciferase-reporting vector containing the RAGE promoter and stimulated with EE. Enhanced luciferase activity was observed in HMEC-1 cells exposed to 3, 10 or 30 nM EE (Fig. 9A) . Although luciferase levels were significantly decreased when the Sp1 sites at À189 (Fig. 9B) and À172 (Fig. 9C) were mutated, induction of luciferase transcription with EE was completely absent when both sites (À189 and À172) in tandem were mutated (Fig. 9D) . Mutations of these Sp1 binding regions demonstrate that these sites are critically important in EE induced RAGE promoter activity.
3.7. Effect of 17-b-E 2 , EE and 17-epiestriol on the activation of NF-jB in HMEC-1 NF-nB is involved in various proinflammatory and prooxidative signaling events. In addition to Sp1, the RAGE promoter contains NF-nB recognition sites. To determine whether the different ER-agonists induced expression of RAGE by activating NF-nB, we performed gel-shift assays using oligodeoxynucleotides corresponding to the NF-nB sites. Specificity of the complexes was determined as described in Fig. 8 and by a supershift assay using an affinity purified polyclonal antibody against NF-nB-p65. The nuclear translocation of NF-nB following treatment with ER-agonists was similar to that observed in the absence of ER-agonists, suggesting that ER-agonists had no effect on the basal level of NF-nB translocation (Fig. 10) .
Discussion
The molecular and cellular mechanisms by which estrogens influence cardiovascular complications in diabetic subjects are just beginning to be elucidated. One recent study demonstrated that treatment of human endothelial cells with 17-h-E 2 induced RAGE expression [6] . RAGE is a cell surface molecule of the immunoglobulin superfamily [21] that is involved in the progression of cardiovascular complications in diabetic animal models [22, 23] . Elevated RAGE expression is also observed in human atherosclerotic plaques further supporting the involvement of this receptor in atherosclerosis [24] . Although two types of ER (ERa and ERh) are involved in mediating estrogen's actions [7] , the specific role of ERa or ERh in stimulating RAGE expression has not been determined. Thus, the aim of this investigation was to examine the functional importance of ERa and ERh specific agonists in the regulation of RAGE expression and to determine the signaling mechanism involved.
To initially evaluate estrogen-induced RAGE expression, HMEC-1 were treated with 17-h-E 2 , which is the major circulating unconjugated estrogen in premenopausal women. 17-h-E 2 binds to ERa and ERh with approximately equal affinity [8] and is therefore used as the prototype by which other estrogens are compared. The results indicated that 17-h-E 2 induced both RAGE mRNA and protein expression (Figs. 1 and 2) . 17-h-E 2 induced RAGE expression only in the absence of the ER antagonist, ICI182780, suggesting that 17-h-E 2 functions via ER (Fig. 3) .
To identify the specific ER responsible for estrogendependent induction of RAGE expression, we next treated HMEC-1 with the ERa agonist EE or the ERh agonist 17-epiestriol. The ERa agonist EE stimulated RAGE expression in HMEC-1 (Fig. 4A) , whereas the ERh agonist 17-epiestriol was substantially less effective (Fig.  4B) . Comparative densitometric analyses demonstrated that EE is the most potent ER agonist for RAGE induction and suggest a role for ERa in the process (Fig. 5) . Using antisense ODN against ERa or ERh we have confirmed that ERa is responsible for 17-h-E 2 -dependent RAGE expression and ERh has a minimal role (Figs. 6 and 7) .
To identify the mechanisms through which estrogens induce RAGE expression in endothelial cells, we sought to determine the transcription factors involved in activation of RAGE. The RAGE promoter does not contain classical estrogen response elements, but has several regions that can bind to either Sp1 or NF-nB [14] . It was previously shown that an interaction of Sp1/ER complex with GCrich motifs in the promoter region is required for the transcriptional activation of several estrogen responsive genes [14] . Further studies demonstrated that domains of ERa are required for ERa/Sp1-mediated activation of GC rich promoters (motifs) by estrogens and antiestrogens in breast cancer cells [25 -27] . In the present study, we demonstrate that 17-h-E 2 and EE activated Sp1 in HMEC-1 (Fig. 8) . EE was more potent than 17-h-E 2 . In addition, 17-epiestriol only minimally stimulated Sp1 activation. Moreover, ERa appeared to mediate estrogen-dependent activation of Sp1 since interaction of an anti-ERa antibody with nuclear extracts derived from 17-h-E 2 treated HMEC-1 shifted the Sp1 band, while an antiERh antibody did not. This indicates that Sp1 and ERa interact. Finally, the intensity of the Sp1 band induced by the ERa-agonist EE was approximately five times greater than that induced by ERh-agonist 17-epiestriol. Of note, EE and 17-epiestriol are not absolutely specific agonists for ERa and ERh, respectively, but may have weak affinity for the other ER [8] . We propose that the low level stimulation of RAGE protein expression by higher concentrations of 17-epiestriol was due to its low affinity for ERa.
To confirm the role of Sp1 in induction of the RAGE promoter, we analyzed the Sp1 sites using luciferase promoter reporter constructs. These studies demonstrated that EE induced RAGE promoter activity via interaction Fig. 10 . Electrophoretic mobility shift assay showing the effects of 17-h-E 2 , EE and 17-epiestriol on the activation of NF-nB in HMEC-1: HMEC-1 were treated with 10 nM concentration of 17-h-E 2 , EE and 17-epiestriol for 2 h and nuclear extracts prepared. Then, 10 Ag of nuclear extract was loaded per lane. Lanes 1 and 2, experiments were performed in the presence of either wild type oligonucleotide (Wt Oligo) alone or mutant oligonucleotide (Mut Oligo) respectively. Lane 3, nuclear extract obtained from untreated control. Lane 4, nuclear extract obtained from 10 nM 17-h-E 2 treatments. Lane 5, the specificity of the assay was evaluated by incubating 17-h-E 2 -treated nuclear extracts with p65 antibody (supershift analysis). Lanes 6 and 7, nuclear extract obtained from EE and 17-epiestriol-treated cells. This figure is representative of three different experiments.
with proximal Sp1 binding sites (Fig. 9) . The EE enhanced promoter activity was prevented when Sp1 sites (À189 and À172) in the RAGE promoter were mutated.
Previously we determined that TNFa-induced activation of RAGE expression in human endothelial cells via the activation of NF-nB (unpublished). We also demonstrated that estrogens attenuated TNFa-dependent activation of NFnB and subsequent expression of VCAM-1 [10] . Although the RAGE promoter contains several NF-nB binding sites [14] , the results of the present investigation indicate that nuclear translocation of NF-nB following treatment with ER-agonists was similar to that observed in the absence of ER-specific agonists (untreated control), suggesting no involvement of NF-nB in ER-agonist-induced RAGE expression (Fig. 10) .
In conclusion, the results of this investigation demonstrate that in cultured HMEC-1, the ERa agonist EE mediates ER-dependent RAGE expression and the ERh agonist 17-epiestriol has a minimal role in RAGE induction. These findings indicate that physiologic levels of estrogens differentially regulate pro-inflammatory actions (e.g., RAGE expression) through a and h estrogen receptors. Moreover, estrogen-induced RAGE expression is an EREindependent transcriptional event, and Sp1 but not NF-nB plays a key role.
